uniQure NV (FRA:UQ1) Cyclically Adjusted Revenue per Share: €1.91 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UQ1 uniQure NV FRA:UQ1
48 GF Score
Price €40.10
GF Value €6.23
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is uniQure NV Cyclically Adjusted Revenue per Share?

uniQure NV FRA:UQ1 +5.53% 48 Cyclically Adjusted Revenue per Share is €1.91 as of Jun. 2026. GuruFocus rates FRA:UQ1 with a GF Score™ of 48/100 and a GF Value™ of €6.23 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

uniQure NV's adjusted revenue per share for the three months ended in Jun. 2026 was €0.077. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.91 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of uniQure NV was 1.50% per year. The lowest was 1.50% per year. And the median was 1.50% per year.

As of today (2026-08-08), uniQure NV's current stock price is €40.10. uniQure NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €1.91. uniQure NV's Cyclically Adjusted PS Ratio of today is 20.99.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of uniQure NV was 31.78. The lowest was 1.86. And the median was 7.46.


uniQure NV  (FRA:UQ1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

uniQure NV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=40.10/1.91
=20.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of uniQure NV was 31.78. The lowest was 1.86. And the median was 7.46.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


uniQure NV Cyclically Adjusted Revenue per Share Related Terms


uniQure NV Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for uniQure NV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

uniQure NV Cyclically Adjusted Revenue per Share Chart

uniQure NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.87 1.77 1.98 1.82

uniQure NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.82 1.83 1.82 1.65 1.91

FRA:UQ1 vs ATAI, RARE, CLDX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, uniQure NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


uniQure NV Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where uniQure NV's Cyclically Adjusted PS Ratio falls into.


FRA:UQ1
48GF Score
uniQure NV FRA:UQ1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

uniQure NV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, uniQure NV's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.077/137.7700*137.7700
=0.077

Current CPI (Jun. 2026) = 137.7700.

uniQure NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.256 100.570 0.351
201612 0.343 100.710 0.469
201703 0.122 101.440 0.166
201706 0.172 101.370 0.234
201709 0.074 102.030 0.100
201712 0.070 101.970 0.095
201803 0.089 102.470 0.120
201806 0.072 103.100 0.096
201809 0.072 103.950 0.095
201812 0.038 103.970 0.050
201903 0.027 105.370 0.035
201906 0.058 105.840 0.075
201909 0.023 106.700 0.030
201912 0.054 106.800 0.070
202003 0.002 106.850 0.003
202006 0.031 107.510 0.040
202009 0.034 107.880 0.043
202012 0.626 107.850 0.800
202103 0.008 108.870 0.010
202106 8.204 109.670 10.306
202109 0.037 110.790 0.046
202112 1.086 114.010 1.312
202203 0.035 119.460 0.040
202206 0.010 119.050 0.012
202209 0.031 126.890 0.034
202212 2.068 124.940 2.280
202303 0.105 124.720 0.116
202306 0.047 125.830 0.051
202309 0.028 127.160 0.030
202312 0.128 126.450 0.139
202403 0.161 128.580 0.173
202406 0.213 129.910 0.226
202409 0.042 131.610 0.044
202412 0.102 131.630 0.107
202503 0.027 133.330 0.028
202506 0.083 133.960 0.085
202509 0.054 135.920 0.055
202512 0.076 135.270 0.077
202603 0.049 136.910 0.049
202606 0.077 137.770 0.077

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.91 mean?
uniQure NV (FRA:UQ1) has a Cyclically Adjusted Revenue per Share of €1.91 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on uniQure NV and its competitors.
Is uniQure NV's Cyclically Adjusted Revenue per Share too high?
uniQure NV's current Cyclically Adjusted Revenue per Share is €1.91. Overall, uniQure NV has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Cyclically Adjusted Revenue per Share compare to ATAI and RARE?
uniQure NV's Cyclically Adjusted Revenue per Share of €1.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on uniQure NV and its competitors. uniQure NV's current Cyclically Adjusted Revenue per Share is €1.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (FRA:UQ1) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.23, compared to a current price of €40.10 — trading 543.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.91. uniQure NV's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For uniQure NV (FRA:UQ1), the current Cyclically Adjusted Revenue per Share is €1.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is uniQure NV (FRA:UQ1) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of €40.10 is trading 543.7% above its estimated GF Value™ of €6.23. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for FRA:UQ1:

  • Cyclically Adjusted Revenue per Share: €1.91
  • GF Value™: €6.23 vs. price of €40.10 (543.7% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the FRA:UQ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


uniQure NV Business Description

Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
48GF Score

Get the complete analysis for FRA:UQ1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.10
Price
€6.23
GF Value